Fully integrated specialty biopharmaceutical company Listed on Tel-Aviv stock exchange in
2005 (TASE: KMDA)
State of the art, cGMP compliant manufacturing facility tailored to produce specialty
life saving pharmaceuticals using proprietary patented technology
Revenue from the sale of approved specialty pharmaceuticals, distributed through international strategic collaborations
Late-stage clinical pipeline focused on niche biopharmaceuticals for several respiratory diseases including alpha-1-deficiency, cystic fibrosis and bronchiectasis
220 highly qualified employees
Traded Shares and Option
|
TYPE
|
NAME
|
SYMBOL
|
|
Share
|
KAMADA
|
KMDA
|
-
Main Business Lines
- Development, production and sale of high added-value, specialty life-saving products *
- Distribution of pharmaceuticals
- R&D and protein purification services
- Cooperation with strategic partners
